文献速递膀胱癌与上尿路尿路上皮癌

机器人辅助肾输尿管切除术:超过1100例患者的手术与中期肿瘤学结局(ROBUUST 2.0协作组)

Robot-assisted nephroureterectomy: surgical and mid-term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group).
PubMed 文献 · BJU Int · 2024-09-12

基于ROBUUST 2.0国际多中心注册数据库,纳入2015至2022年接受机器人辅助肾输尿管切除术(RANU)的1118例上尿路尿路上皮癌患者。术后并发症率为14.1%,切缘阳性率为4.7%,3年无复发生存率为59%、无转移生存率为76%、总生存率为76%、肿瘤特异性生存率为88%。结论认为RANU手术并发症低,中期肿瘤学结局可与开放手术相媲美。

要点

  • RANU术后并发症率为14.1%,切缘阳性率为4.7%。
  • 3年无复发生存率59%、无转移生存率76%、总生存率76%、肿瘤特异性生存率88%。
  • 膀胱袖状切除、高级别肿瘤、病理T分期≥3及淋巴结受累为更差肿瘤学结局的显著预测因素。

核心结论

  • 本研究为支持越来越多采用RANU的证据体系增添了证据,该手术并发症低,中期肿瘤学结局良好,与开放肾输尿管切除术相当,即使在非器官局限性病变中也是如此。

研究设计与样本

  • 数据来自ROBUUST 2.0数据库,该数据库为国际多中心注册研究,纳入2015至2022年间接受根治性手术的上尿路尿路上皮癌患者。
  • 分析纳入所有连续接受RANU的患者,排除预测因素数据缺失者,共1118例。
  • 生存分析采用Kaplan-Meier法,以3年为截点,并建立多变量Cox比例风险模型评估各肿瘤学结局的预测因素。

主要发现

  • 术后并发症率为14.1%,切缘阳性率为4.7%。
  • 术后估算肾小球滤过率中位数(四分位距)较基线下降-13.1(-27.5至0)mL/min/1.73 m2。
  • 3年无复发生存率为59%,3年无转移生存率为76%,3年总生存率为76%,3年肿瘤特异性生存率为88%。
  • 更差肿瘤学结局的显著预测因素为膀胱袖状切除、高级别肿瘤、病理T分期≥3及淋巴结受累。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyse surgical, functional, and mid-term oncological outcomes of robot-assisted nephroureterectomy (RANU) in a contemporary large multi-institutional setting. PATIENTS AND METHODS: Data were retrieved from the ROBotic surgery for Upper tract Urothelial cancer STtudy (ROBUUST) 2.0 database, an international, multicentre registry encompassing data of patients with upper urinary tract urothelial carcinoma undergoing curative surgery between 2015 and 2022. The analysis included all consecutive patients undergoing RANU except those with missing data in predictors. Detailed surgical, pathological, and postoperative functional data were recorded and analysed. Oncological time-to-event outcomes were: recurrence-free survival (RFS), metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS). Survival analysis was performed using the Kaplan-Meier method, with a 3-year cut-off. A multivariable Cox proportional hazard model was built to evaluate predictors of each oncological outcome. RESULTS: A total of 1118 patients underwent RANU during the study period. The postoperative complications rate was 14.1%; the positive surgical margin rate was 4.7%. A postoperative median (interquartile range) estimated glomerular filtration rate decrease of -13.1 (-27.5 to 0) mL/min/1.73 m2 from baseline was observed. The 3-year RFS was 59% and the 3-year MFS was 76%, with a 3-year OS and CSS of 76% and 88%, respectively. Significant predictors of worse oncological outcomes were bladder-cuff excision, high-grade tumour, pathological T stage ≥3, and nodal involvement. CONCLUSIONS: The present study contributes to the growing body of evidence supporting the increasing adoption of RANU. The procedure consistently offers low surgical morbidity and can provide favourable mid-term oncological outcomes, mirroring those of open NU, even in non-organ-confined disease.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ditonno F, Franco A, Wu Z, et al. Robot-assisted nephroureterectomy: surgical and mid-term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group). BJU Int. 2024. PMID: 39263834. doi:10.1111/bju.16526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。